

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.
ARBN	152 854 923

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neville Mitchell
Date of last notice	4 September 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	CHESS Depositary Interests (CDIs) held by N J Mitchell Superannuation Fund <i>(Neville Mitchell has a beneficial interest in the above Fund)</i>	
Date of change	11 May 2018 (AEST)* 15 May 2018 (AEST)**	
No. of securities held prior to change	85,000	Options with exercise price of US\$0.97 per Share
	50,000	Options with exercise price of A\$1.31 per Share
	30,000	Options with exercise price of A\$1.16 per Share
	50,000	Options with exercise price of A\$0.82 per Share
	Total: <u>215,000</u> Options (exercisable into an equivalent of 430,000 CDIs) <u>178,494</u> CDIs held by N J Mitchell Superannuation Fund <i>(Neville Mitchell has a beneficial interest in the above Fund)</i>	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Options over Shares (not quoted) CDIs (quoted)	
Number acquired	61,250* Options (exercisable into an equivalent of 122,500 CDIs) 250,000** CDIs	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL* \$47,500**	
No. of securities held after change	85,000	Options with exercise price of US\$0.97 per Share
	50,000	Options with exercise price of A\$1.31 per Share
	30,000	Options with exercise price of A\$1.16 per Share
	50,000	Options with exercise price of A\$0.82 per Share
	61,250	Options with exercise price of A\$0.38 per Share
	Total: 276,250 Options (exercisable into an equivalent of 552,500 CDIs) 428,494 CDIs held by N J Mitchell Superannuation Fund (Neville Mitchell has a beneficial interest in the above Fund)	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	*Issue of Options to Neville Mitchell was in accordance with the Osprey Medical 2016 Stock Incentive Plan. The grant of Options was approved by stockholders on 10 May 2018 as part of the Company's Annual Stockholder meeting. **On-market purchase of CDIs	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.